A61P 13 - Drugs for disorders of the urinary system

Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
10/2001
10/25/2001	CA2370572A1 Kv10.1, a novel voltage-gated potassium channel from human brain
10/24/2001	EP1147776A2 Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
10/24/2001	EP1147775A2 Use of botulinum toxin type B for the manufacture of a medicament for reducing pain associated with a muscle disorder
10/24/2001	EP1147769A2 Use of polyunsaturated fatty acids, especially omega-3-fatty acids, for the treatment of enuresis and incontinence
10/24/2001	EP1147121A2 Ketolide antibiotics
10/24/2001	EP1147110A1 Pyrazino(aza)indole derivatives
10/24/2001	EP1147102A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1147097A1 Peptidyl heterocyclic ketones useful as tryptase inhibitors
10/24/2001	EP1147095A1 2, 3, 4, 5-tetrahydro-1h-[1, 4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
10/24/2001	EP1147092A1 Substituted imidazoles, their preparation and use
10/24/2001	EP1147091A2 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
10/24/2001	EP1147089A1 Phenylphenanthridines with pde-iv inhibiting activity
10/24/2001	EP1147078A1 Acetylenic (beta)-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1146892A2 Baff, inhibitors thereof and their use in the modulation of the b-cell response
10/24/2001	EP1146888A2 Specific therapeutic interventions obtained by interference with redistribution and/or targetting
10/24/2001	EP1146885A1 Pre-conditioning against cell death
10/24/2001	EP1146870A1 Antioxidant compositions and methods for companion animals
10/24/2001	EP1035824A4 A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
10/24/2001	EP0854721B1 Endothelin receptor antagonists
10/24/2001	CN1319139A Polynucleotide constructs and uses thereof
10/24/2001	CN1319133A Short peptides which selectively modulate activity of protein kinases
10/24/2001	CN1319097A Benzoxazine and benzothiazine derivatives and their use in medicines
10/24/2001	CN1319096A Quinazoline derivatives and pharmaceutical applications thereof
10/24/2001	CN1319094A Imidazolyl derivatives
10/24/2001	CN1319093A Aminoalkyl-3,4-dihydroquindine derivates as No-synthase inhibitors
10/24/2001	CN1319009A Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
10/24/2001	CN1318407A Chinese medicine for treating prostata proliferation and hypertrophy
10/24/2001	CN1318390A Nephrotic syndrome treating Chinese medicine composition
10/24/2001	CN1318372A Application of insulin sensitizing agent in treatment of nephrosis
10/24/2001	CN1073557C Vitamin-D amide derivatives
10/23/2001	US6307092 Potent ocular hypotensives and are particularly suited for the management of glaucoma.
10/23/2001	US6307060 Antispasmodic agents
10/23/2001	US6307022 Def
10/23/2001	US6306897 Calanolides for inhibiting BTK
10/23/2001	US6306879 Isotonic glucose solution
10/23/2001	US6306852 Indole derivatives useful as endothelin receptor antagonists
10/23/2001	US6306827 Method for preventing and/or treating renal disease
10/23/2001	US6306819 Method for regulating size of vascularized normal tissue
10/23/2001	US6306654 Nucleotide sequence coding mutant gonadotrophin hormone; for treatment of reproduction defects
10/23/2001	US6306392 Prevention and/or treatment of alterations of those organs which perform metabolic function, such as liver, kidneys, cardiovascular system and brain; for therapy of hepatosis, nephropathies and cardiovascular or cerebral damage damage
10/23/2001	CA2236368C Sublingual and buccal administration of selegiline
10/23/2001	CA2087606C (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
10/18/2001	WO2001077378A2 Diagnosis of diseases associated with dna adducts
10/18/2001	WO2001077377A2 Diagnosis of diseases associated with dna replication by assessing dna methylation
10/18/2001	WO2001077376A2 Diagnosis of diseases associated with metastasis
10/18/2001	WO2001077375A2 Diagnosis of diseases associated with gene regulation
10/18/2001	WO2001077174A2 Human transporters and ion channels
10/18/2001	WO2001077166A1 Novel physiologically active peptides and use thereof
10/18/2001	WO2001077164A2 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis
10/18/2001	WO2001077149A2 Regulation of human cyslt2-like gpcr protein
10/18/2001	WO2001077146A2 Compounds and methods for modulating endothelial cell adhesion
10/18/2001	WO2001077139A1 8ss-HYDROCARBYL-SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS
10/18/2001	WO2001077138A1 8β-SUBSTITUTED-11β-PENTYL- AND 11β-HEXYL-ESTRA-1,3,5(10)-TRIENE DERIVATIVES
10/18/2001	WO2001077137A1 Albumin fusion proteins
10/18/2001	WO2001077110A1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
10/18/2001	WO2001077104A1 Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
10/18/2001	WO2001077100A2 Benzoamide piperidine compounds as substance p antagonists
10/18/2001	WO2001077093A1 Estrogen agonist/antagonist metabolites
10/18/2001	WO2001077092A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/18/2001	WO2001077089A1 New neurokinin antagonists for use as medicaments
10/18/2001	WO2001077085A1 Quinazoline compounds
10/18/2001	WO2001077069A1 Naphthamide neurokinin antagonists for use as medicaments
10/18/2001	WO2001077057A2 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	WO2001076693A1 Inhibitors of prenyl-protein transferase
10/18/2001	WO2001076586A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
10/18/2001	WO2001076584A2 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001	WO2001076574A2 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
10/18/2001	WO2001076573A2 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
10/18/2001	WO2001076572A2 Use of compatible solutes as substances having free radical scavenging properties
10/18/2001	WO2001076568A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/18/2001	WO2001076530A2 Il-8 receptor antagonists
10/18/2001	WO2001076451A2 Diagnosis of diseases associated with metabolism
10/18/2001	WO2001052873A8 VEGETABLE OIL FOR PREPARING A COMPOSITION INHIBITING 5α- REDUCTASE ACTIVITY
10/18/2001	WO2000039283A9 Use of cd40 engagement to alter t cell receptor usage
10/18/2001	US20010031882 Lipoxin compounds and their use in treating cell proliferative disorders
10/18/2001	US20010031782 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
10/18/2001	US20010031777 Heterocyclic compounds and their therapeutic use
10/18/2001	US20010031757 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, N'-((1-(Aminoiminomethyl)4-piperidinyl) methyl)-N-(3,3- diphenylpropionyl)-L-proline amide
10/18/2001	US20010031260 Administering tumor necrosis factor antagonist; rheumatic diseases, skin disorders
10/18/2001	DE10019167A1 New 8 beta-substituted 11 beta-(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives, are ovary-selective estrogen receptor ligands useful e.g. as female or male contraceptives or for treating ovarian carcinoma
10/18/2001	DE10013782A1 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln 4-fluoroalkyl-2H-benzopyrans with antiestrogenic action, processes for their preparation, pharmaceutical compositions containing them and their use for the preparation of medicaments
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405895A1 Combination of organic compounds
10/18/2001	CA2405793A1 Combination of organic compounds
10/18/2001	CA2405476A1 Compounds and methods for modulating endothelial cell adhesion
10/18/2001	CA2405411A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001	CA2405089A1 Benzoamide piperidine containing compounds and related compounds
10/18/2001	CA2405070A1 Estrogen agonist/antagonist metabolites
10/18/2001	CA2404229A1 Human transporters and ion channels
10/18/2001	CA2404087A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
10/18/2001	CA2403365A1 Quinazoline compounds
10/18/2001	CA2403144A1 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	CA2372352A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/17/2001	EP1146035A1 Crystal polymorphism of aminoethylphenoxyacetic acid derivative
10/17/2001	EP1144648A1 Cyclic nucleotide-associated proteins
10/17/2001	EP1144628A2 Human vanilloid receptor gene
10/17/2001	EP1144614A2 33 human secreted proteins
10/17/2001	EP1144605A2 Dimethylarginine dimethylaminohydrolases
10/17/2001	EP1144600A2 Akt-3 nucleic acids, polypeptides, and uses thereof
10/17/2001	EP1144598A2 Human homologues of proteins regulated by circadian rhythms

1 ... 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 ... 562